Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
57.56M | 50.58M | 47.68M | 50.83M | 45.85M | Gross Profit |
39.69M | 29.75M | 28.29M | 35.84M | 32.88M | EBIT |
-30.77M | -15.10M | -42.07M | -34.68M | -42.89M | EBITDA |
-26.62M | 1.18M | -39.58M | -45.11M | -39.15M | Net Income Common Stockholders |
-44.14M | -7.87M | -60.20M | -90.04M | -65.36M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
71.55M | 23.87M | 27.27M | 28.02M | 31.81M | Total Assets |
101.42M | 57.42M | 55.67M | 61.99M | 62.88M | Total Debt |
38.00M | 33.32M | 56.09M | 56.42M | 40.48M | Net Debt |
-33.54M | 9.45M | 28.82M | 28.40M | 8.67M | Total Liabilities |
161.58M | 163.91M | 174.23M | 144.13M | 111.38M | Stockholders Equity |
-60.16M | -106.49M | -118.55M | -82.13M | -48.50M |
Cash Flow | Free Cash Flow | |||
-35.92M | -7.38M | -12.31M | -33.89M | -45.98M | Operating Cash Flow |
-35.76M | -6.38M | -9.79M | -32.98M | -45.46M | Investing Cash Flow |
-159.00K | -995.00K | -2.52M | -913.00K | -517.00K | Financing Cash Flow |
83.59M | 3.97M | 11.56M | 30.11M | 28.46M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $2.87B | 12.33 | 38.89% | ― | 31.85% | ― | |
68 Neutral | $10.69B | 33.14 | 14.16% | ― | 24.81% | 33.67% | |
64 Neutral | $1.79B | 24.29 | 7.55% | ― | 8.94% | 5171.26% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
48 Neutral | $30.37M | ― | 210.50% | ― | 1.63% | 6.97% | |
44 Neutral | $261.02M | ― | 77.48% | ― | 13.80% | -389.41% | |
42 Neutral | $241.55M | ― | -31.41% | ― | 389.82% | -22.66% |
Aquestive Therapeutics has announced its plans to advance several product candidates through clinical development and potential FDA approval. The company’s pipeline includes Anaphylm, a sublingual film for epinephrine delivery, and AQST-108, a topical gel for alopecia areata. Additionally, the company is working on expanding market access for its epilepsy treatment, Libervant, despite challenges related to orphan drug exclusivity. These developments could significantly impact Aquestive’s market position and offer new treatment options for patients.
Aquestive Therapeutics reported its financial results for the fourth quarter and full year of 2024, highlighting the initiation of the Anaphylm NDA filing process with the FDA, with a potential launch in early 2026. The company also announced progress in its AQST-108 topical gel development for alopecia areata, aiming to start Phase 2a trials in 2025. Despite a decrease in total revenues by 10% compared to the previous year, the company is advancing its strategic priorities, including the launch of Libervant for young ARS patients, although facing legal challenges regarding its FDA approval.
Aquestive Therapeutics has provided a business update, highlighting its progress and strategic goals for 2025. The company is preparing to submit a New Drug Application for Anaphylm™, an epinephrine sublingual film, in early 2025, aiming for approval and market launch by the first quarter of 2026. Aquestive is also advancing its AQST-108 topical gel for alopecia areata, with a Phase 2a clinical trial scheduled for mid-2025. The company has received FDA approval for Libervant®, a buccal film for seizure clusters in young pediatric patients, and is focusing on expanding its market reach for these innovative treatments, suggesting an optimistic outlook for capturing market share in these therapeutic areas.